Published in Nat Commun on April 18, 2016
IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells. Oncotarget (2016) 0.79
Phytochemicals Approach for Developing Cancer Immunotherapeutics. Front Pharmacol (2017) 0.76
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Microenvironmental regulation of metastasis. Nat Rev Cancer (2008) 15.76
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 12.36
PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 12.26
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
Breast cancer metastasis: markers and models. Nat Rev Cancer (2005) 9.93
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet (1999) 9.53
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J (1992) 8.86
Identification of p53 as a sequence-specific DNA-binding protein. Science (1991) 6.60
IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity (2001) 6.56
The metastatic niche: adapting the foreign soil. Nat Rev Cancer (2009) 5.28
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med (2002) 5.18
Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol (2009) 4.90
New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. J Immunol (2002) 4.48
Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med (2011) 4.25
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res (2010) 3.53
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med (2012) 2.58
Localization of gene for human p53 tumour antigen to band 17p13. Nature (1986) 2.56
IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J Biol Chem (2001) 2.50
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2005) 2.47
Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol (2010) 2.24
TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep (2012) 2.20
Sustained growth and three-dimensional organization of primary mammary tumor epithelial cells embedded in collagen gels. Proc Natl Acad Sci U S A (1979) 2.15
Mast cells produce interleukin-25 upon Fc epsilon RI-mediated activation. Blood (2003) 1.95
Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet (1999) 1.93
Non-invasive detection of a small number of bioluminescent cancer cells in vivo. PLoS One (2010) 1.92
Forced expression of murine IL-17E induces growth retardation, jaundice, a Th2-biased response, and multiorgan inflammation in mice. J Immunol (2001) 1.89
Preparation of ready-to-use, storable and reconstituted type I collagen from rat tail tendon for tissue engineering applications. Nat Protoc (2006) 1.69
Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther (2002) 1.52
Docetaxel: a review of its use in metastatic breast cancer. Drugs (2005) 1.47
IL-17E upregulates the expression of proinflammatory cytokines in lung fibroblasts. J Allergy Clin Immunol (2006) 1.37
Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI-1. Curr Biol (2000) 1.33
Cutting edge: CTLA-4 on effector T cells inhibits in trans. J Immunol (2012) 1.26
Mechanism of interleukin-25 (IL-17E)-induced pulmonary inflammation and airways hyper-reactivity. Clin Exp Allergy (2006) 1.24
Genomic organization of the human KAI1 metastasis-suppressor gene. Genomics (1997) 1.23
Dual targeting of epigenetic therapy in cancer. Biochim Biophys Acta (2006) 1.11
IL-25 causes apoptosis of IL-25R-expressing breast cancer cells without toxicity to nonmalignant cells. Sci Transl Med (2011) 1.11
Cancer cells suppress p53 in adjacent fibroblasts. Oncogene (2008) 1.10
Macrophages as IL-25/IL-33-responsive cells play an important role in the induction of type 2 immunity. PLoS One (2013) 1.09
The receptor for interleukin-17E is induced by Th2 cytokines in antigen-presenting cells. Scand J Immunol (2004) 1.03
Docetaxel: its role in current and future treatments for advanced gastric cancer. Gastric Cancer (2009) 1.00
IL-25 induces M2 macrophages and reduces renal injury in proteinuric kidney disease. J Am Soc Nephrol (2011) 0.96
A theoretical framework for quantitative analysis of the molecular basis of costimulation. J Immunol (2005) 0.89
Synthesis and biological evaluation of dihydrobenzofuran lignans and related compounds as potential antitumor agents that inhibit tubulin polymerization. J Med Chem (1999) 0.87
Retracted A dihydrobenzofuran lignan induces cell death by modulating mitochondrial pathway and G2/M cell cycle arrest. J Med Chem (2009) 0.81
Antiangiogenic activity of synthetic dihydrobenzofuran lignans. J Nat Prod (2002) 0.80
Optical molecular imaging in drug discovery and clinical development. Expert Opin Drug Discov (2007) 0.79
Isolation and characterization of the human genomic locus coding for the putative metastasis control gene nm23-H1. Hum Genet (1994) 0.79
Traditional Chinese medicine herbal extracts of Cibotium barometz, Gentiana scabra, Dioscorea batatas, Cassia tora, and Taxillus chinensis inhibit SARS-CoV replication. J Tradit Complement Med (2011) 0.77
Anticancer efficacy of unique pyridine-based tetraindoles. Eur J Med Chem (2015) 0.75